Stockmarketfunding

http://www.StockMarketFunding.com Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst Market Manipulation? Wall St is hyping the suicidal results. We believe today's "pre market" manipulation in price action caused some large institutions to take a short position going into the move and the FDA Program Schedule Released at 8 AM today did not show any meaningful new data. Premarket high was $29.50 and now we're trading at $24.50 $5 dollars lower. The new breakthrough in Human Genome Sciences Benlysta drug approval for lupus patients. SMF will cover the pros and the cons of the HGSI new drug and benefits to humanity. We will take a look at one of the most positive developments in "biotechnology" in the past 50 years. We have highlighted HGSI and the longer term trends relative to the current drug developments. BENLYSTA is an investigational human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognize and inhibit the biological activi